I
I-MAB
NASDAQ: IMAB (I-MAB)
Kemas kini terakhir: semalam, 8:24AM4.25
-0.02 (-0.47%)
| Penutupan Terdahulu | 4.27 |
| Buka | 4.30 |
| Jumlah Dagangan | 598,027 |
| Purata Dagangan (3B) | 1,882,343 |
| Modal Pasaran | 533,681,856 |
| Harga / Jualan (P/S) | 25.39 |
| Harga / Buku (P/B) | 2.42 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2025 |
| EPS Cair (TTM) | -0.550 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.86% |
| Nisbah Semasa (MRQ) | 22.35 |
| Aliran Tunai Operasi (OCF TTM) | -52.67 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -68.15 M |
| Pulangan Atas Aset (ROA TTM) | -11.05% |
| Pulangan Atas Ekuiti (ROE TTM) | -19.70% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | I-MAB | Menaik | Menaik |
AISkor Stockmoo
0.0
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 0.0 |
| Purata | 0.00 |
|
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People’s Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 10.80% |
| % Dimiliki oleh Institusi | 29.64% |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |